Portfolio News
Sofinnova Industrial Biotech
AFYREN announces the resumption of production at its plant after the successful technical shutdown
Clermont-Ferrand/Lyon, July 6, 2026, 07:30 am CEST – AFYREN, a greentech company offering manufacturers biobased, low-carbon ingredients through a unique fermentation technology based on a circular model, announces the resumption of production at the AFYREN NEOXY plant after the successful technical shutdown of June.
As part of the consolidation and performance improvement plan launched in 2025, AFYREN scheduled a one-month technical shutdown in June 2026 to modify existing and install new equipment in the downstream process.
The works proceeded as planned and on budget: four weeks of work, six days out of seven, for a total 20,000 working hours and a total investment of around €6 million.
Up to 90 people have been working on site on certain days, drawn from around a dozen external companies, doubling the usual workforce at the AFYREN NEOXY plant. In the challenging conditions of intense heat, team safety remained the top priority throughout the shutdown, with zero accident with loss time reported.
Following the works, production has resumed, and AFYREN expects an acceleration in production in the second half of 2026, after a first semester which saw revenue doubling compared with FY 2025.
Nicolas SORDET, Chief Executive Officer of AFYREN, commented: “Thanks to exemplary planning by the teams and robust execution, the planned technical shutdown was completed on schedule despite the intense heat, which required adjustments to working hours. All equipment modifications have been completed, which will be a major driver for accelerating production in the second half of the year. I would like to thank the AFYREN Group teams and all contractor companies for completing the work on time, within budget, and while maintaining safe working conditions.”
To read the full press release: https://afyren.com/en/blog/afyren-announces-the-resumption-of-production-at-its-plant-after-the-successful-technical-shutdown/
Related News
Inventiva Strengthens Board of Directors with Appointment of Three Distinguished Life Sciences Leaders
Abivax Announces Closing of $920 Million Public Offering
Genespire and SR-TIGET Show Durable Preclinical Efficacy of Liver-Directed Gene Therapy for Methylmalonic Acidemia
Sofinnova Partners announces Myricx Bio agrees to be acquired by Novartis
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)